Faculty Profiles - NINOMIYA Kiichiro

MISC - NINOMIYA Kiichiro

Division display 1 - 20 of about 122 ／ All the affair displays >>

RWDからNecitumumabによる低Mg血症を考察する多施設共同後方視的観察(NINJA Study)からの提言

森雅秀, 丹澤盛, 鉄本訓史, 田中洋史, 渡部聡, 山口覚博, 吉原健, 中尾明, 久保昭仁, 横山俊彦, 渡邉香奈, 鶴野広介, 吉岡弘鎮, 宮内栄作, 二宮貴一朗, 三角俊裕, 関順彦

肺癌 63 ( 5 ) 659 - 659 2023.10

サブグループ解析は臨床を変えうるのか?~肺癌学会サブグループ解析検討委員会報告~

森田智視, 寺岡俊輔, 大矢由子, 森瀬昌宏, 二宮貴一朗, 阪本智宏, 田中謙太郎, 三浦理

日本呼吸器学会誌(Web) 12 2023

ゲノム情報を有効に活用するための診療体制の構築

中田英二, 藤原智洋, 国定俊之, 遠西大輔, 二宮貴一朗, 冨田秀太, 二川摩周, 山本英喜, 平沢晃, 田端雅弘, 豊岡伸一, 尾崎敏文

日本整形外科学会雑誌 97 ( 6 ) 2023

Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.

Yuka Kato, Taku Noumi, Kazuhiko Saeki, Kiichiro Ninomiya, Toshio Kubo, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Masahiro Tabata, Katsuyuki Hotta, Toshiyuki Kozuki, Yoshinobu Maeda, Katsuyuki Kiura

JOURNAL OF CLINICAL ONCOLOGY 39 ( 15 ) 2021.5

肺癌診療ガイドラインにおける臨床諸問題ガイドラインに採用されるサブグループ解析とは?

二宮貴一朗

日本呼吸器学会誌 10 ( 増刊 ) 31 - 31 2021.4

レンバチニブが有効であった右上顎腺様嚢胞癌の一例

西達也, 西森久和, 亀井裕子, 二宮貴一朗, 加藤有加, 久保寿夫, 堀田勝幸, 田端雅弘, 木浦勝行, 前田嘉信

日本内科学会雑誌 110 ( Suppl. ) 169 - 169 2021

Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer

二宮貴一朗, 大熊裕介, 海老規之, 青景圭樹, 大矢由子, 阪本智宏, 上月稔幸, 野崎要, 白井克幸, 野中哲生, 里内美弥子, 石川仁, 堀田勝幸, 滝口裕一

肺癌(Web) 61 ( 2 ) 2021

The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives

滝口裕一, 瀬戸貴司, 野崎要, 長谷川一男, 森田智視, 守田亮, 二宮貴一朗, 樋田豊明

肺癌(Web) 61 ( 3 ) 2021

災害ボランティア後にアスペルギローマとアレルギー性気管支肺アスペルギルス症を合併した一例

久保寿夫, 中須賀崇匡, 谷口暁彦, 二宮貴一朗, 大橋圭明, 頼冠名, 堀田勝幸, 宮原信明, 田端雅弘, 木浦勝行

気管支学 43 ( Suppl. ) S284 - S284 2021

What are the features of the subgroup analysis adopted for the JLCS guidelines?

二宮貴一朗

日本呼吸器学会誌(Web) 10 2021

The 2020 edition of the clinical guidelines for lung cancer: Challenges and future perspectives

Yuichi Takiguchi, Takashi Seto, Kaname Nosaki, Kazuo Hasegawa, Satoshi Morita, Ryo Morita, Kiichiro Ninomiya, Toyoaki Hida

Japanese Journal of Lung Cancer 61 ( 3 ) 163 - 170 2021

Language：Japanese Publishing type：Book review, literature introduction, etc. Publisher：Japan Lung Cancer Society

Objective. To improve the clinical guidelines for lung cancer. Methods. By focusing on the discussion topics at a symposium held in the annual meeting of the Japan Lung Cancer Society 2020 and the results of two independent external evaluations of the guidelines, the history, advantages and limitations of the guidelines were reviewed with respect to problems to be solved. Results. The guidelines were established in 2003 and have been updated annually since 2011. Their contemporary and scientific validity are highly evaluated by external evaluations, whereas the constitutive framework has found to be lacking in many aspects. Rapid advancement in molecular target therapy and therapy with immune checkpoint inhibitors has forced changes in the methodology of clinical trials and in statistical interpretation, resulting in multiple recommendations for a certain specific disease condition. It is important to address the wide diversity of values used for the evaluation of therapeutic outcomes. Conclusion. Problems include heterogeneity in clinical trials, the methodology of interpretation and individual values. Although various medical staff, biostatisticians and patients were already involved in the process of preparing the guidelines, much wider discussion among various stakeholders should be undertaken to solve these problems and improvements that reflect external evaluation should be implemented.

DOI： 10.2482/haigan.61.163

Scopus

researchmap

Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer

Kiichiro Ninomiya, Yusuke Okuma, Noriyuki Ebi, Keiju Aokage, Yuko Oya, Tomohiro Sakamoto, Toshiyuki Kozuki, Kaname Nosaki, Katsuyuki Shirai, Tetsuo Nonaka, Miyako Satouchi, Hitoshi Ishikawa, Katsuyuki Hotta, Yuichi Takiguchi

Japanese Journal of Lung Cancer 91 ( 2 ) 95 - 99 2021

Language：Japanese Publishing type：Book review, literature introduction, etc. Publisher：Japan Lung Cancer Society

The standard treatment for non-small-cell lung cancer (NSCLC) with distant metastases is pharmacotherapy, and the survival benefit of additional localized therapy has not been clarified. However, in cases of oligometastatic disease in which metastatic lesions are limited, a long-term prognosis has been observed with localized therapy. In recent years, several randomized controlled trials have reported the effects of additional localized therapy for oligometastatic disease. These trials have targeted cases of synchronous oligometastatic disease, and all have tended to show the extension of the survival period. Treatment of NSCLC is diversifying due to the advent of novel strategies, such as targeted therapy, immune checkpoint inhibitors, and radiotherapeutic technology. Localized therapy for oligometastatic disease might be a new treatment strategy, although the disadvantages of its invasiveness and the risks associated with discontinuation of pharmacotherapy need to be considered.

DOI： 10.2482/HAIGAN.61.95

Scopus

researchmap

肺癌診療ガイドライン(薬物):過去10年の軌跡とこれからの未来ガイドラインに求めるもの作成側の視点

二宮貴一朗

肺癌 60 ( 6 ) 466 - 466 2020.10

肺癌免疫療法・支持療法非小細胞肺癌化学放射線療法における食道炎に対するアルギン酸Naの有用性を検討する無作為化比較試験(OLCSG1401)

久山彰一, 工藤健一郎, 尾形毅, 二宮貴一朗, 尾瀬功, 吉岡弘鎮, 別所昭宏, 細川忍, 上月稔幸, 原田大二郎, 八杉昌幸, 村上斗司, 中西将元, 瀧川奈義夫, 勝井邦彰, 前田嘉信, 堀田勝幸, 木浦勝行

日本呼吸器学会誌 9 ( 増刊 ) 129 - 129 2020.8

左上顎洞腫瘤を契機に発見された左心室内への浸潤を伴う肺神経内分泌癌(小細胞癌)の集学的治療の一例

平生敦子, 加藤有加, 西達也, 岡崎幹生, 二宮貴一朗, 二宮崇, 久保寿夫, 頼冠名, 市原英基, 大橋圭明, 山根正修, 堀田勝幸, 田端雅弘, 豊岡伸一, 前田嘉信, 木浦勝行

日本肺癌学会総会号 61st ( 6 ) 683 - 683 2020

A randomized trial of sodium alginate for preventing radiation esophagitis in pts with locally advanced non-small-cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT): OLCSG1401

久山彰一, 久山彰一, 工藤健一郎, 工藤健一郎, 尾形毅, 二宮貴一朗, 尾瀬功, 吉岡弘鎮, 別所昭宏, 細川忍, 上月稔幸, 原田大二郎, 八杉昌幸, 村上斗司, 中西将元, 瀧川奈義夫, 勝井邦彰, 前田嘉信, 堀田勝幸, 木浦勝行

日本呼吸器学会誌(Web) 9 2020

ガイドラインに求めるもの:作成側の視点

二宮貴一朗

日本肺癌学会総会号 61st 2020

非小細胞肺癌領域における新規医薬品に基づく医薬品開発に係る臨床試験デザインについての検討

加藤有加, 堀田勝幸, 二宮貴一朗, 久保寿夫, 頼冠名, 市原英基, 大橋圭明, 田端雅弘, 前田嘉信, 木浦勝行

日本肺癌学会総会号 61st ( 6 ) 534 - 534 2020

Egfr改変肺癌マウスモデルを用いたEGFR-TKI,抗VEGFR-2抗体と抗PD-1抗体併用療法の検討

西井和也, 大橋圭明, 中須賀崇匡, 平生敦子, 大川祥, 渡邉洋美, 狩野裕久, 原尚史, 安東千裕, 二宮貴一朗, 加藤有加, 二宮崇, 久保寿夫, 頼冠名, 市原英基, 堀田勝幸, 田端雅弘, 鵜殿平一郎, 前田嘉信, 木浦勝行

日本肺癌学会総会号 61st ( 6 ) 531 - 531 2020

SHP2阻害剤は遺伝子変異陽性肺癌細胞株における分子標的薬の効果を増強する

狩野裕久, 市原英基, 大川祥, 平生敦子, 安東千裕, 中須賀崇匡, 原尚史, 西井和也, 渡邉洋美, 二宮貴一朗, 加藤有加, 二宮崇, 久保寿夫, 頼冠名, 大橋圭明, 堀田勝幸, 田端雅弘, 前田嘉信, 木浦勝行

日本肺癌学会総会号 61st ( 6 ) 529 - 529 2020

　 PREV - NEXT 　

< NINOMIYA Kiichiro >

MISC - NINOMIYA Kiichiro